Thryv Therapeutics to Showcase SGK1 Inhibitors at Major Healthcare Conferences
Thryv Therapeutics to Showcase SGK1 Inhibitors at Major Healthcare Conferences
Thryv Therapeutics Inc., a biotechnology company focused on developing innovative therapies, has announced its participation in key healthcare conferences in New York City. This initiative aims to update investors on their promising pipeline of SGK1 inhibitors, which are designed to treat inherited and acquired cardiometabolic diseases. Among the recent advancements is the active enrollment in a critical clinical trial for the drug THRV-1268, intended for the treatment of Long QT Syndrome (LQTS).
Upcoming Investor Conferences
Thryv will be featured in three prominent healthcare conferences this spring:
1. UBS Global Healthcare Conference 2026
Dates: May 18–19, 2026
Presentation Date: May 18, at 1:15 PM ET
Location: New York, NY
Format: Company presentation followed by one-on-one investor meetings.
2. RBC Capital Markets Global Healthcare Conference 2026
Dates: May 19–20, 2026
Presentation Date: May 19, at 10:30 AM ET
Location: New York, NY
Format: Company presentation and individual investor meetings.
3. Jefferies Global Healthcare Conference 2026
Dates: June 2–4, 2026
Location: New York, NY
Format: Focused one-on-one investor meetings.
Investors interested in attending these conferences and scheduling meetings can reach out via their dedicated email.
Pipeline Progress of SGK1 Inhibitors
Thryv Therapeutics is at the forefront of developing selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target cardiometabolic diseases, enabling potential therapeutic breakthroughs. The company’s lead compound, THRV-1268, is under investigation in a Phase 2/3 clinical trial for Long QT Syndrome, a serious genetic heart rhythm condition.
Recently, THRV-1268 received the FDA Fast Track designation, indicating the urgency of its development pathway due to the significant unmet clinical needs in treating LQTS. Thryv plans a New Drug Application (NDA) submission by 2028. This therapeutic approach could mark the first disease-modifying treatment approved for this condition.
In addition, the company is gearing up for a Phase 2a study focusing on heart failure with preserved ejection fraction (HFrEF), set to commence shortly. This study is pivotal as it targets a high-risk segment of heart failure affecting approximately one million patients in the United States.
A Broader Vision for Cardiometabolic Health
Thryv’s commitment extends beyond LQTS, as it seeks to apply its SGK1 inhibitor platform to a variety of prevalent cardiometabolic disorders, including heart failure and cardiomyopathies. The company aims to establish itself as a leader in precision medicine specifically tailored to genetic arrhythmias and related diseases.
“We are eager to engage with investors and share our progress in developing innovative therapies targeted at high-risk cardiovascular populations,” said the company’s leadership. “Our work reflects a deep commitment to addressing significant healthcare challenges with our state-of-the-art SGK1 inhibitors.”
For more information on Thryv Therapeutics and their groundbreaking work, visit Thryv’s official website.
Conclusion
As Thryv Therapeutics prepares for these significant investor conferences, the company remains poised to make a substantial impact in the field of cardiometabolic diseases through its innovative SGK1 inhibitors. The anticipation surrounding THRV-1268 and the broader therapeutic platform underscores the importance of clinical advancements in improving patient outcomes in high-risk populations.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.